Publications by authors named "Jose Manuel Conde-Sanchez"
How to obtain a 3D printed model of renal cell carcinoma (RCC) with venous tumor thrombus extension (VTE) for surgical simulation (phase I NCT03738488).
Updates Surg
December 2020
Article Synopsis
- This phase 1 clinical trial (NCT03738488) aims to evaluate the effectiveness of using 3D models for surgical planning in cases of renal cell carcinoma (RCC) with venous tumor thrombus extension (VTE), compared to traditional CT images.
- A specific protocol was established for converting CT images into accurate, reproducible, and cost-effective 3D printed models, utilizing software like ITK-snap and VirSSPA for segmentation.
- After testing with ten different models, four were finalized that accurately represented the anatomy, maintained structural integrity during surgery simulations, and were produced with a standardized, affordable printing process, with average design and printing costs of about €33.4 and 38.5 hours
Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review.
Urol Int
January 2021
Nivolumab is a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody that selectively blocks the interaction between PD-1, which is expressed on activated T cells, and its ligands PD-L1 and PD-L2, which are expressed on immune cells and tumour cells. Patients with severe renal dysfunction and haemodialysis are not enrolled in clinical trials. However, in daily clinical practice, we have patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease (ESRD).
View Article and Find Full Text PDFObjective: To examine the connection between preoperative thrombocytosis and hematocrit and survival in a group of patients operated for renal cell carcinoma.
Methods: Retrospective study with descriptive and statistical analysis of 139 patients with renal cell carcinoma treated surgically over the last 4 years in our Urology clinical unit. 116 (83,45%)were diagnosed at a localized clinical stage, whereas 23 (16,54%) presented as locally advanced or metastatic disease.